TMO
Thermo Fisher Scientific Inc.570.16
-5.75-1%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
FY Q4 '25
Cautious optimism on biopharma rebound
Q&A revealed cautiously optimistic pharma/biotech signals, with Casper citing upbeat January meetings, CEO anecdotes on trusted partner wins, and biotech funding uptick despite six-month spending lag—framing the 3-4% organic guide as conservative sans 2025's pandemic runoff. Sterile fill-finish demand stays hot, fueling pharma services growth via reshoring contracts. AI complements wet labs, spurring more experimentation. Academic/government outlook mirrors last year's caution until NIH budget clears. Answers reaffirmed scripted story. Pharma sentiment lifted distinctly. Management tone: confident, prudent; watch funding flow-through.
Last Quarter (Q3 '25)
FY Q3 '25
Reshoring tailwinds, clinical acceleration
Q&A spotlighted pharma customers' confidence navigating tariffs through U.S. reshoring, driving near-term demand for bioprocessing equipment and Patheon fill-finish capacity while startup activity adds incremental tailwinds. Clinical research accelerated to low-single-digit growth with strong authorizations and accelerator program wins, especially in biotech. Management reaffirmed 3-6% organic trajectory into 2026, unpacking Solventum ($750M revenue, $0.06 dilutive) and Sanofi ($0.05 dilutive) details. Academic/government muted by shutdown hesitancy, baked into Q4 guide; China declines mid-high single digits. Bioproduction bookings outpace strong teens growth. Investors eye reshoring ramp.
Key Stats
Market Cap
214.21BP/E (TTM)
32.90Basic EPS (TTM)
17.33Dividend Yield
0%Recent Filings
8-K
8-K
Q4 revenue up 7%
Thermo Fisher Scientific reported Q4 revenue up 7% to $12.21 billion and full-year revenue up 4% to $44.56 billion, with GAAP EPS rising 9% to $5.21 quarterly and 7% to $17.74 annually. Acquisitions fueled growth, including Solventum's Filtration business and Sanofi's sterile site, while announcing Clario buyout; $16.5 billion deployed total, yet organic growth lagged at 3% Q4, 2% yearly. Strong execution persists.
8-K
Exec departures, leadership reshuffle
Thermo Fisher Scientific disclosed executive departures: COO Michel Lagarde exits March 31, 2026, and EVP Frederick M. Lowery leaves February 28, 2026, both for other opportunities. Effective March 1, leadership shifts with Marc N. Casper as Chairman and CEO, Gianluca Pettiti promoted to President and COO, and Michael Shafer to expanded EVP role reporting to CEO. Restructuring streamlines operations. No successor details provided.
8-K
€2.1B euro notes issued
Thermo Fisher International issued €1B floating rate senior notes due 2027 and €1.1B 3.628% fixed rate senior notes due 2035 on December 1, 2025, fully guaranteed by the parent company. Net proceeds of ~€2.09B target general corporate purposes like acquisitions or debt refinancing. Covenants limit liens on key assets. Change of control triggers repurchase offers.
10-Q
Q3 FY2025 results
Thermo Fisher Scientific posted solid Q3 results, with revenues climbing 5% year-over-year to $11.1B, fueled by 3% organic growth (derived) from robust bioproduction demand in pharma and biotech, while academic spending cooled amid uncertainty. Operating income edged up 6% to $1.9B, lifting the margin to 17.4%, thanks to productivity gains that offset restructuring costs and acquisition impacts; diluted EPS held steady at $4.27. Acquisitions like the $3.9B Solventum filtration business bolstered Life Sciences Solutions, adding $2.1B in goodwill, and a pending $8.9B Clario deal eyes clinical trial expansion by mid-2026. Cash dipped to $2.0B with $3.3B FCF (derived) supporting $3.0B in buybacks, while total debt rose to $35.7B under a $5B revolver with no draws. Yet regulatory hurdles could snag that Clario close.
IPO
Website
Employees
Sector
Industry
A
Agilent Technologies, Inc.
139.19-1.41
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BRKR
Bruker Corporation
44.96-0.71
DGX
Quest Diagnostics Incorporated
178.66-5.45
DHR
Danaher Corporation
224.70-3.83
ILMN
Illumina, Inc.
131.56-3.36
QGEN
Qiagen N.V.
45.01-0.43
RVTY
Revvity, Inc.
96.27-2.81
TWST
Twist Bioscience Corporation
31.13+0.06
WAT
Waters Corporation
378.53-6.89